DK2086981T3 - Forbindelser til inhibering af mitoseprogression - Google Patents

Forbindelser til inhibering af mitoseprogression

Info

Publication number
DK2086981T3
DK2086981T3 DK07867449.6T DK07867449T DK2086981T3 DK 2086981 T3 DK2086981 T3 DK 2086981T3 DK 07867449 T DK07867449 T DK 07867449T DK 2086981 T3 DK2086981 T3 DK 2086981T3
Authority
DK
Denmark
Prior art keywords
compounds
inhibiting mitosis
mitosis progression
progression
inhibiting
Prior art date
Application number
DK07867449.6T
Other languages
Danish (da)
English (en)
Inventor
Christopher F Claiborne
Todd B Sells
Stephen G Stroud
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39315133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2086981(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of DK2086981T3 publication Critical patent/DK2086981T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK07867449.6T 2006-11-16 2007-11-14 Forbindelser til inhibering af mitoseprogression DK2086981T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85934006P 2006-11-16 2006-11-16
PCT/US2007/023948 WO2008063525A1 (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression

Publications (1)

Publication Number Publication Date
DK2086981T3 true DK2086981T3 (da) 2012-08-06

Family

ID=39315133

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07867449.6T DK2086981T3 (da) 2006-11-16 2007-11-14 Forbindelser til inhibering af mitoseprogression
DK12153131.3T DK2497772T3 (en) 2006-11-16 2007-11-14 A compound for inhibiting mitotic progression

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK12153131.3T DK2497772T3 (en) 2006-11-16 2007-11-14 A compound for inhibiting mitotic progression

Country Status (34)

Country Link
US (7) US8026246B2 (enExample)
EP (4) EP2497773B1 (enExample)
JP (3) JP5102839B2 (enExample)
KR (2) KR101110458B1 (enExample)
CN (2) CN101547924B (enExample)
AR (1) AR064246A1 (enExample)
AT (1) ATE556076T1 (enExample)
AU (1) AU2007322046B2 (enExample)
BR (1) BRPI0718803B8 (enExample)
CA (1) CA2669680C (enExample)
CL (1) CL2007003244A1 (enExample)
CR (3) CR10782A (enExample)
CY (1) CY1112828T1 (enExample)
DK (2) DK2086981T3 (enExample)
EA (1) EA015779B1 (enExample)
ES (3) ES2384123T3 (enExample)
GE (1) GEP20125459B (enExample)
HR (2) HRP20120490T1 (enExample)
IL (1) IL198690A0 (enExample)
MA (1) MA30988B1 (enExample)
MX (3) MX348568B (enExample)
MY (1) MY153243A (enExample)
NO (1) NO343338B1 (enExample)
NZ (3) NZ611898A (enExample)
PH (1) PH12012502057B1 (enExample)
PL (2) PL2497772T3 (enExample)
PT (2) PT2086981E (enExample)
RS (2) RS52313B (enExample)
SG (2) SG10201503350TA (enExample)
SI (2) SI2086981T1 (enExample)
TW (1) TWI401255B (enExample)
UA (1) UA94129C2 (enExample)
WO (1) WO2008063525A1 (enExample)
ZA (1) ZA200903279B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101792651B1 (ko) 2004-05-14 2017-11-20 밀레니엄 파머슈티컬스 인코퍼레이티드 아우로라 키나아제의 억제에 의해 유사분열 진행을 억제하기 위한 화합물 및 그 화합물을 포함하는 약학적 조성물
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
US7998952B2 (en) * 2008-12-05 2011-08-16 Millennium Pharmaceuticals, Inc. Thiolactams and uses thereof
CN102264368B (zh) 2008-12-22 2014-09-10 米伦纽姆医药公司 极光激酶抑制剂与抗cd20抗体的组合
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
WO2011103089A1 (en) 2010-02-19 2011-08-25 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6--methoxyphenyl)-5h -pyrimido[5,4-d][2]benzazepin-2yl]amino}-2-methoxybenzoate
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
EP2585465B1 (en) * 2010-06-22 2014-11-12 GlaxoSmithKline LLC Benzotriazolodiazepine compounds inhibitors of bromodomains
AR086656A1 (es) * 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
US20130303519A1 (en) * 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN103772391A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
EP2976086B1 (en) * 2013-03-22 2020-10-14 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
EP3236948A4 (en) * 2014-12-23 2018-10-03 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
EP3324976A4 (en) 2015-07-21 2019-03-27 Millennium Pharmaceuticals, Inc. ADMINISTRATION OF KINASE AURORA INHIBITOR AND CHEMOTHERAPEUTIC AGENTS
JP6955485B2 (ja) 2015-09-09 2021-10-27 アイカーン スクール オブ メディスン アット マウント サイナイＩｃａｈｎ Ｓｃｈｏｏｌ ｏｆ Ｍｅｄｉｃｉｎｅ ａｔ Ｍｔ． Ｓｉｎａｉ 抗がん剤としての複素環式の限定された三環系スルホンアミド
JP6966425B2 (ja) 2015-09-09 2021-11-17 アイカーン スクール オブ メディスン アット マウント サイナイIcahn School of Medicine at Mt. Sinai 抗がん剤としての複素環式の限定された三環系スルホンアミド
WO2017146253A1 (ja) 2016-02-26 2017-08-31 公益財団法人がん研究会 Ｈｐ１の機能に着目した抗癌剤のスクリーニング方法及び評価系
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
JP6188986B1 (ja) * 2017-03-23 2017-08-30 株式会社ノエビア 時計遺伝子発現量調整剤及びエラスチン産生促進剤
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
US20250228848A1 (en) 2022-04-07 2025-07-17 Eli Lilly And Company Process for making a kras g12c inhibitor
CA3247183A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company TREATMENT METHOD INCLUDING KRAS G12C INHIBITORS AND AURORA A INHIBITORS
KR20250027777A (ko) 2022-06-30 2025-02-27 일라이 릴리 앤드 캄파니 암을 치료하기 위한 kras g12c 억제제
IL327467A (en) 2023-10-03 2026-05-01 Takeda Pharmaceutical Co Limited Elisartib and paclitaxel for the treatment of small cell lung cancer
WO2025245045A1 (en) 2024-05-21 2025-11-27 The Regents Of The University Of California Methods of treating lung cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) * 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
US4481142A (en) * 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
SU1181547A3 (ru) 1979-02-07 1985-09-23 Ф.Хоффманн-Ля Рош Унд Ко,Аг (Фирма) Способ получени пиримидо-2-бензазепинов или их фармакологически совместимых кислотно-аддитивных солей (и его вариант)
US4469633A (en) * 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) * 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) * 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
EP0888350A1 (en) 1996-03-08 1999-01-07 Zeneca Limited Azolobenzazepine derivatives as neurologically active agents
AU5330698A (en) * 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
DK1026167T3 (da) * 1997-09-29 2003-05-26 Meiji Seika Kaisha Tricykliske triazolobenzazepinderivater, fremgangsmåde til fremstilling af disse samt antiallergiske midler
US6277844B1 (en) * 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
DE60039782D1 (de) 1999-12-06 2008-09-18 Ajinomoto Kk Amidinophenylbrenztraubensäure-derivat
BR0116493A (pt) * 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) * 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
HUP0401107A3 (en) 2001-08-09 2004-10-28 Actelion Pharmaceuticals Ltd Novel benzo-fused heterocycles, their use process for their preparation and pharmaceutical compositions containing them
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
KR101792651B1 (ko) 2004-05-14 2017-11-20 밀레니엄 파머슈티컬스 인코퍼레이티드 아우로라 키나아제의 억제에 의해 유사분열 진행을 억제하기 위한 화합물 및 그 화합물을 포함하는 약학적 조성물
MX2007005857A (es) 2004-11-17 2007-10-10 Mikana Therapeutics Inc Inhibidores de cinasa.
EP1836188A1 (en) 2004-12-30 2007-09-26 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
WO2007076348A2 (en) 2005-12-23 2007-07-05 Smithkline Beecham Corporation Azaindole inhibitors of aurora kinases
WO2008021038A2 (en) 2006-08-09 2008-02-21 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها

Also Published As

Publication number Publication date
JP5452811B2 (ja) 2014-03-26
HK1134672A1 (en) 2010-05-07
BRPI0718803B1 (pt) 2020-11-17
PT2497772E (pt) 2015-02-05
ZA200903279B (en) 2010-07-28
MX348568B (es) 2017-06-20
RS53788B1 (sr) 2015-06-30
KR20090091173A (ko) 2009-08-26
BRPI0718803B8 (pt) 2021-05-25
PL2086981T3 (pl) 2012-09-28
WO2008063525A1 (en) 2008-05-29
IL198690A0 (en) 2010-02-17
EP2086981A1 (en) 2009-08-12
AR064246A1 (es) 2009-03-25
ES2528793T3 (es) 2015-02-12
PH12012502057A1 (en) 2015-09-14
EP2944639A1 (en) 2015-11-18
MA30988B1 (fr) 2009-12-01
US20150166545A1 (en) 2015-06-18
MY153243A (en) 2015-01-29
HRP20120490T1 (hr) 2012-07-31
MX343391B (es) 2016-11-04
SI2086981T1 (sl) 2012-12-31
KR101342014B1 (ko) 2013-12-19
US9765076B2 (en) 2017-09-19
US20240400567A1 (en) 2024-12-05
US20210214361A1 (en) 2021-07-15
US20190031662A1 (en) 2019-01-31
CR10782A (es) 2009-06-24
NZ577042A (en) 2012-03-30
NO343338B1 (no) 2019-02-04
NZ611898A (en) 2015-01-30
SI2497772T1 (sl) 2015-03-31
US8026246B2 (en) 2011-09-27
EP2497772A1 (en) 2012-09-12
NO20091864L (no) 2009-06-15
PL2497772T3 (pl) 2015-05-29
CL2007003244A1 (es) 2008-04-04
AU2007322046A1 (en) 2008-05-29
HK1175777A1 (en) 2013-07-12
RS52313B (sr) 2012-12-31
US10836766B2 (en) 2020-11-17
GEP20125459B (en) 2012-03-26
EP2497773A1 (en) 2012-09-12
US20110312943A1 (en) 2011-12-22
JP5102839B2 (ja) 2012-12-19
EA200970486A1 (ru) 2009-10-30
EP2497773B1 (en) 2015-02-25
US20080167292A1 (en) 2008-07-10
EP2086981B1 (en) 2012-05-02
CN103483343B (zh) 2016-06-01
SG10201503350TA (en) 2015-06-29
NZ597252A (en) 2013-06-28
ES2384123T3 (es) 2012-06-29
CR20140544A (es) 2015-01-12
JP2014055166A (ja) 2014-03-27
MX2009004670A (es) 2009-05-15
PT2086981E (pt) 2012-06-20
EP2497772B1 (en) 2014-10-29
AU2007322046B2 (en) 2012-04-05
TWI401255B (zh) 2013-07-11
CA2669680C (en) 2012-04-10
US11958855B2 (en) 2024-04-16
HK1175778A1 (en) 2013-07-12
CA2669680A1 (en) 2008-05-29
ATE556076T1 (de) 2012-05-15
CN101547924A (zh) 2009-09-30
TW200829589A (en) 2008-07-16
UA94129C2 (ru) 2011-04-11
EP2944639B1 (en) 2017-01-04
CN103483343A (zh) 2014-01-01
US20110312942A1 (en) 2011-12-22
DK2497772T3 (en) 2015-01-19
EA015779B1 (ru) 2011-12-30
CY1112828T1 (el) 2016-02-10
BRPI0718803A2 (pt) 2013-12-03
HRP20150047T1 (en) 2015-03-13
JP2012006965A (ja) 2012-01-12
KR101110458B1 (ko) 2012-03-13
KR20110113210A (ko) 2011-10-14
JP2010510215A (ja) 2010-04-02
CR20140154A (es) 2014-07-23
HK1217699A1 (en) 2017-01-20
SG176443A1 (en) 2011-12-29
ES2537451T3 (es) 2015-06-08
PH12012502057B1 (en) 2018-10-24
US9988384B2 (en) 2018-06-05
CN101547924B (zh) 2013-09-25

Similar Documents

Publication Publication Date Title
LTC2004635I2 (lt) Pakeistieji enaminokarbonilo junginiai
DK3178792T3 (da) Fremgangsmåde til aflejringshæmning
DK2068927T3 (da) Fremgangsmåder til reducering af eosinofilniveauer
DK1737461T3 (da) Carbolin-derivater til inhibering af angiogenese
ATE556076T1 (de) Verbindungen zur hemmung von mitoseprogression
DK1974807T3 (da) Fremgangsmåde til fjernelse af endokrint forstyrrende forbindelser
DK2431359T3 (da) Fremgangsmåde til fremstilling af diaminophenothiaziniumforbindelser
BRPI0815042A2 (pt) Compostos de pirazol
BRPI0813500A2 (pt) Compostos antivirais
ATE502948T1 (de) Substituierte bicyclolactamverbindungen
BRPI0821086A2 (pt) Compostos inseticidas
DK2001892T3 (da) Imidazolthiazolforbindelser til behandling af proliferative sygdomme
DK2035166T3 (da) Fremgangsmåde til fremstilling af beholdere
ATE524477T1 (de) Aziridinylepothilonverbindungen
BRPI0922880A2 (pt) compostos inibidores de quinase
DK2073636T3 (da) Fremgangsmåde til fremstilling af oxymorphon
BRPI0811264A2 (pt) Compostos
BRPI0720097A2 (pt) Compostos de fosfonato
BRPI0809996A2 (pt) Compostos
BRPI0814424A2 (pt) Compostos heterociclila
DK2061746T3 (da) Fremgangsmåde til fremstilling af diestere
BRPI0815181A2 (pt) Compostos
DK2214929T3 (da) Køretøj til håndtering af styrtgods
DK2387591T3 (da) Copolymer til inhibering af uorganiske aflejringer
BRPI0814613A2 (pt) Compostos